AGILON HEALTH INC (AGL)

US00857U1079 - Common Stock

1.85  -0.12 (-6.09%)

After market: 1.86 +0.01 (+0.54%)

Fundamental Rating

2

Taking everything into account, AGL scores 2 out of 10 in our fundamental rating. AGL was compared to 108 industry peers in the Health Care Providers & Services industry. Both the profitability and financial health of AGL have multiple concerns. While showing a medium growth rate, AGL is valued expensive at the moment.



Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year AGL has reported negative net income.
In the past year AGL has reported a negative cash flow from operations.
In the past 5 years AGL always reported negative net income.
AGL had a negative operating cash flow in each of the past 5 years.

1.2 Ratios

AGL's Return On Assets of -18.40% is on the low side compared to the rest of the industry. AGL is outperformed by 78.50% of its industry peers.
AGL's Return On Equity of -66.94% is on the low side compared to the rest of the industry. AGL is outperformed by 70.09% of its industry peers.
Industry RankSector Rank
ROA -18.4%
ROE -66.94%
ROIC N/A
ROA(3y)-15.66%
ROA(5y)-26.12%
ROE(3y)-29.05%
ROE(5y)-181.24%
ROIC(3y)N/A
ROIC(5y)N/A

1.3 Margins

Looking at the Gross Margin, with a value of 2.00%, AGL is doing worse than 84.11% of the companies in the same industry.
In the last couple of years the Gross Margin of AGL has declined.
AGL does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 2%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-23.83%
GM growth 5YN/A

More info and screens

3

2. Health

2.1 Basic Checks

AGL does not have a ROIC to compare to the WACC, probably because it is not profitable.
AGL has less shares outstanding than it did 1 year ago.
The debt/assets ratio for AGL has been reduced compared to a year ago.

2.2 Solvency

Based on the Altman-Z score of 1.58, we must say that AGL is in the distress zone and has some risk of bankruptcy.
AGL has a Altman-Z score (1.58) which is comparable to the rest of the industry.
A Debt/Equity ratio of 0.06 indicates that AGL is not too dependend on debt financing.
With a decent Debt to Equity ratio value of 0.06, AGL is doing good in the industry, outperforming 77.57% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.06
Debt/FCF N/A
Altman-Z 1.58
ROIC/WACCN/A
WACC9.26%

2.3 Liquidity

A Current Ratio of 1.29 indicates that AGL should not have too much problems paying its short term obligations.
AGL has a Current ratio of 1.29. This is in the lower half of the industry: AGL underperforms 60.75% of its industry peers.
AGL has a Quick Ratio of 1.29. This is a normal value and indicates that AGL is financially healthy and should not expect problems in meeting its short term obligations.
With a Quick ratio value of 1.29, AGL perfoms like the industry average, outperforming 46.73% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 1.29
Quick Ratio 1.29

More info and screens

6

3. Growth

3.1 Past

The earnings per share for AGL have decreased strongly by -254.55% in the last year.
AGL shows a strong growth in Revenue. In the last year, the Revenue has grown by 27.75%.
AGL shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 52.45% yearly.
EPS 1Y (TTM)-254.55%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-262.5%
Revenue 1Y (TTM)27.75%
Revenue growth 3Y52.45%
Revenue growth 5YN/A
Sales Q2Q%19.35%

3.2 Future

AGL is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 22.54% yearly.
The Revenue is expected to grow by 18.97% on average over the next years. This is quite good.
EPS Next Y-16.52%
EPS Next 2Y9.27%
EPS Next 3Y15.21%
EPS Next 5Y22.54%
Revenue Next Year34.85%
Revenue Next 2Y21.96%
Revenue Next 3Y19.72%
Revenue Next 5Y18.97%

3.3 Evolution

The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

AGL reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for AGL. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A

4.3 Compensation for Growth

A more expensive valuation may be justified as AGL's earnings are expected to grow with 15.21% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y9.27%
EPS Next 3Y15.21%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for AGL!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

AGILON HEALTH INC

NYSE:AGL (12/23/2024, 8:04:00 PM)

After market: 1.86 +0.01 (+0.54%)

1.85

-0.12 (-6.09%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)11-07 2024-11-07/amc
Earnings (Next)N/A N/A
Inst Owners87.22%
Inst Owner Change-6.13%
Ins Owners1.78%
Ins Owner Change9.71%
Market Cap762.24M
Analysts54.81
Price Target3.53 (90.81%)
Short Float %10.48%
Short Ratio7.45
Dividend
Industry RankSector Rank
Dividend Yield N/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-78.49%
Min EPS beat(2)-171.08%
Max EPS beat(2)14.11%
EPS beat(4)2
Avg EPS beat(4)-43.31%
Min EPS beat(4)-171.08%
Max EPS beat(4)18.64%
EPS beat(8)3
Avg EPS beat(8)-31.01%
EPS beat(12)3
Avg EPS beat(12)-48.98%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-4.08%
Min Revenue beat(2)-5.86%
Max Revenue beat(2)-2.29%
Revenue beat(4)1
Avg Revenue beat(4)-1.6%
Min Revenue beat(4)-5.86%
Max Revenue beat(4)2.73%
Revenue beat(8)5
Avg Revenue beat(8)1.12%
Revenue beat(12)9
Avg Revenue beat(12)1.54%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-46.94%
PT rev (3m)-52.21%
EPS NQ rev (1m)-3.14%
EPS NQ rev (3m)-32.9%
EPS NY rev (1m)-45.81%
EPS NY rev (3m)-60.28%
Revenue NQ rev (1m)0.26%
Revenue NQ rev (3m)3.11%
Revenue NY rev (1m)0.41%
Revenue NY rev (3m)0.51%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.14
P/FCF N/A
P/OCF N/A
P/B 1.33
P/tB 1.6
EV/EBITDA N/A
EPS(TTM)-0.78
EYN/A
EPS(NY)-0.39
Fwd EYN/A
FCF(TTM)-0.44
FCFYN/A
OCF(TTM)-0.33
OCFYN/A
SpS12.99
BVpS1.4
TBVpS1.16
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -18.4%
ROE -66.94%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 2%
FCFM N/A
ROA(3y)-15.66%
ROA(5y)-26.12%
ROE(3y)-29.05%
ROE(5y)-181.24%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-23.83%
GM growth 5YN/A
F-Score2
Asset Turnover2.56
Health
Industry RankSector Rank
Debt/Equity 0.06
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 191.38%
Cap/Sales 0.83%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.29
Quick Ratio 1.29
Altman-Z 1.58
F-Score2
WACC9.26%
ROIC/WACCN/A
Cap/Depr(3y)160.53%
Cap/Depr(5y)101.54%
Cap/Sales(3y)0.88%
Cap/Sales(5y)0.67%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-254.55%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-262.5%
EPS Next Y-16.52%
EPS Next 2Y9.27%
EPS Next 3Y15.21%
EPS Next 5Y22.54%
Revenue 1Y (TTM)27.75%
Revenue growth 3Y52.45%
Revenue growth 5YN/A
Sales Q2Q%19.35%
Revenue Next Year34.85%
Revenue Next 2Y21.96%
Revenue Next 3Y19.72%
Revenue Next 5Y18.97%
EBIT growth 1Y-142.68%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year39.27%
EBIT Next 3Y28.55%
EBIT Next 5Y24.92%
FCF growth 1Y-13.99%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-4.33%
OCF growth 3YN/A
OCF growth 5YN/A